articleThe Lancet OncologyFeb 11, 2010Closed access

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study

DMDavid M. ThomasRMRobert M. HenshawKMKeith M. SkubitzSPSant P. ChawlaAPArthur P. Staddon

Peter MacCallum Cancer Centre · Georgetown University · +7 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

708
total citations
FWCI
28.71
Percentile
100%
References
32
Citations per year

Authors

12

Topics & keywords

Topics
Keywords
  • Denosumab
  • Medicine
  • Giant cell
  • RANKL
  • Osteoclast
  • Adverse effect
  • Giant-cell tumor of bone
  • Bone pain
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding